Aluminosilicate Zeolite for Chemotherapy-Induced Neuropathy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for painful polyneuropathies caused by toxic agents, such as chemotherapeutic cytotoxic agents, are inadequate in providing effective pain relief with minimal side effects, and existing therapies are not globally consensus-driven, leading to unmet needs in pain management, especially for severe cases.

Innovation Solution

The use of aluminosilicates, specifically zeolites like clinoptilolite, as a pharmaceutical composition to prevent, reduce, or eliminate neuropathic pain associated with polyneuropathy caused by toxic agents, administered before, simultaneously with, or after exposure to these agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional analgesics are used to treat painful polyneuropathies, then pain relief is provided, but side effects increase and treatment efficacy is insufficient

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces aluminosilicate as an intermediary substance that binds to toxic agents in the gastrointestinal tract, preventing their absorption and subsequent neurotoxic effects. This mediator approach allows treatment of the underlying cause rather than just symptomatic management, improving efficacy while avoiding side effects associated with traditional analgesics

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful toxic agents into beneficial outcomes by using aluminosilicate to bind and eliminate them from the body. The toxic agents that cause polyneuropathy are transformed from harmful substances into removable waste products, thereby treating the root cause of the condition

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If chemotherapeutic cytotoxic agents are administered to treat cancer, then cancer is treated, but painful polyneuropathy is caused as a side effect

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidneuropathic pain

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by administering aluminosilicate before or during chemotherapy treatment to prevent the toxic agents from being absorbed and causing neuropathy. This preventive measure allows full dosing of chemotherapeutic agents while blocking their harmful neurological effects

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

Aluminosilicate serves as an intermediary that selectively binds to chemotherapeutic toxic agents in the gastrointestinal tract, preventing their systemic absorption and subsequent neurotoxic effects, thereby enabling effective cancer treatment without neuropathic complications

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If higher doses of chemotherapeutic agents are administered to improve cancer treatment, then cancer treatment efficacy increases, but neuropathic pain severity increases

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidneuropathy severity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses aluminosilicate as a protective intermediary that enables higher doses of chemotherapeutic agents to be administered by binding to and neutralizing their toxic effects in the gastrointestinal tract, thereby decoupling the relationship between dose and neuropathy severity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary action by pre-administering aluminosilicate to establish protective binding capacity before toxic agents can cause damage, allowing aggressive chemotherapy regimens to be used without proportional increase in neuropathy risk

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Aluminosilicates, particularly zeolites, demonstrate a remarkable therapeutic effect in reducing or eliminating neuropathic pain symptoms in patients with polyneuropathy caused by toxic agents, offering a potentially more effective and safer alternative to traditional analgesics.

Implementation Method 1

The aluminosilicate for use in a method of preventing or treating a painful polyneuropathy... caused by exposition of a patient to toxic agents

Methodology Applied

Scientific EffectAdsorption: Adsorption

Data Source

PatentUS9415064B2Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate

Publication Date: 2016.08.16 HRASCHAN JAKOB

AI summary

Prevention or treatment of painful polyneuropathies caused by toxic agents, i.e. to the prevention, reduction or elimination of the symptoms associated with such polyneuropathies, such as neuropathic pain are disclosed. An aluminosilicate for use in such prevention or treatment, preferably a natural or synthetic zeolite, such as clinoptilolite, is provided. The toxic agent is, in particular, a chemotherapeutic cytotoxic agent.